CCL2 and myeloid sarcoma: Recently, completed clinical trials of the liposomal peptide therapeutic, referred as Xemys, representing MBP peptides 46–62, 124–139, and 147–170 entrapped into the small mannosylated monolayer liposomes (25), revealed a decrease in the levels of monocyte chemoattractant protein-1 (MCP-1/CCL2), macrophage inflammatory protein-1 (MIP-1/CCL4), interleukin (IL)-7, and IL-2 in the serum of treated MS patients (26).